GlassScriptPhysician profile
Debra L Bootin
NPI 1447351135
$1,051.00
in general payments reported to CMS, 2019-2025
14 companies · $214 in 2025
The $214 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $53.83 · 2021: $74.05 · 2022: $128 · 2023: $228 · 2024: $353 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $301.98 | 2022-2024 | Bexsero, Pediarix, Rotarix |
| Cranial Technologies, INC | $167.70 | 2021-2025 | Doc Band |
| Tris Pharma INC | $116.07 | 2020-2025 | Dyanavel Xr, Quillivant |
| Corium, LLC | $96.92 | 2024-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $86.63 | 2020-2021 | |
| Sanofi Pasteur INC. | $83.17 | 2023-2025 | |
| Pfizer INC. | $48.40 | 2025 | |
| Merck Sharp & Dohme LLC | $32.62 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $31.07 | 2023-2024 | Kristalose |
| Cipher Pharmaceuticals US LLC | $22.52 | 2025 | Natroba, Spinosad |
| Ironshore Pharmaceuticals INC. | $16.52 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.22 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.11 | 2021 | |
| Alk-Abello, INC | $15.07 | 2023 | Grastek, Odactra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Bootin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.